Table 2 Univariate and multivariate analysis of factors affecting virologic response after IPTW.

From: Real-world study on the efficacy and safety of different treatment regimens in treatment-naïve CHB patients with high viral load

 

Univariable

Multivariable

OR (95%)

P value

OR (95%)

P value

Age, year

    

< 30

-

 

-

 

> 30

1.129(0.689,1.85)

0.63

  

gender

    

Male

1.25(0.737, 2.121)

0.408

  

Female

-

   

Baseline ALT, U/L

    

> 2ULN

-

   

1 ~ 2ULN

0.275(0.157, 0.481)

< 0.001

0.267(0.144, 0.493)

< 0.001

< 1ULN

0.342(0.143, 0.817)

0.016

0.343(0.131, 0.897)

0.029

HBeAg

    

positive

-

-

  

negative

2.086(0.58,7.504)

0.26

  

Antiviral treatment

    

TAF

-

-

-

-

ETV

0.385(0.159, 0.93)

0.034

0.348(0.129, 0.937)

0.037

TDF

0.932(0.394, 2.204)

0.872

0.826(0.323, 2.114)

0.69

TDF + LdT/ETV

1.168(0.5, 2.731)

0.424

1.304(0.514, 3.311)

0.577

Baseline HBsAg, log10 IU/mL

0.368(0.223, 0.608)

< 0.001

0.6(0.349, 1.033)

0.065

Baseline HBV DNA, log10 IU/mL

0.285(0.162, 0.5)

< 0.001

0.285(0.147, 0.554)

< 0.001

  1. Note: HBsAg: hepatitis B virus surface antigen; HBeAg: hepatitis B virus e antigen; ALT: alanine aminotransferase; eGFR: estimated glomerular filtration rate; ETV, entecavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; LdT: telbivudine. IPTW: inverse probability of treatment weighting. ALT ULN cutoff value: ALT ≤ 30 U/L (male) and ≤ 19 U/L (female).
Back to article page